menu
    • menu
    [{"orgOrder":0,"company":"Zhejiang Medicine Co Ltd","sponsor":"Ambrx Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"ARX788","moa":"HER2","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Zhejiang Medicine Co Ltd","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zhejiang Medicine Co Ltd \/ Zhejiang Medicine Co Ltd","highestDevelopmentStatusID":"9","companyTruncated":"Zhejiang Medicine Co Ltd \/ Zhejiang Medicine Co Ltd"},{"orgOrder":0,"company":"Zhejiang Medicine Co Ltd","sponsor":"Ambrx Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Agreement","leadProduct":"ARX305","moa":"CD70","graph1":"Oncology","graph2":"Phase I","graph3":"Zhejiang Medicine Co Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zhejiang Medicine Co Ltd \/ Zhejiang Medicine Co Ltd","highestDevelopmentStatusID":"6","companyTruncated":"Zhejiang Medicine Co Ltd \/ Zhejiang Medicine Co Ltd"}]

    Find Clinical Drug Pipeline Developments & Deals by Zhejiang Medicine Co Ltd

    Menu

    Zhejiang Medicine Co Ltd

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Zhejiang Medicine Co Ltd

                            China arrow
                            PharmScience R&D
                            Not Confirmed

                            Zhejiang Medicine Co Ltd

                            China arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ARX305

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Ambrx Inc

                            Deal Size : $4.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Ambrx Announces NovoCodex’s Dosing of First Patient with ARX305, Ambrx’s Investigational Antibody Drug Con...

                            Details : ARX305 is the only anti-CD70 ADC in active development that targets CD70, a protein that is overexpressed in a broad range of solid and hematologic tumors, giving it the potential to treat a range of liquid and solid tumor cancers, where CD70 is overexpr...

                            Product Name : ARX305

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Undisclosed

                            November 09, 2022

                            Lead Product(s) : ARX305

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Ambrx Inc

                            Deal Size : $4.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Zhejiang Medicine Co Ltd

                            China arrow
                            PharmScience R&D
                            Not Confirmed

                            Zhejiang Medicine Co Ltd

                            China arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ARX788

                            Therapeutic Area : Oncology

                            Study Phase : Phase II/ Phase III

                            Recipient : Ambrx Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ambrx Presents Phase 1 Trial Data Update and Phase 2/3 Clinical Trial in Progress for Lead Program ARX788

                            Details : Patients who failed prior Kadcyla® (T-DM1) or Enhertu® (DS-8201a) achieved clinical responses, as assessed by RECIST v1.1 in the ACE-Pan Tumor-01 (ARX788-1711) tria.

                            Product Name : ARX788

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Inapplicable

                            December 10, 2020

                            Lead Product(s) : ARX788

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II/ Phase III

                            Recipient : Ambrx Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth